Chapter 3

Metformin pre- and postconditioning to reduce ischemia reperfusion injury in an isolated ex vivo rat and porcine kidney normothermic machine perfusion model

Tobias M. Huijink
Leonie H. Venema
Rene A. Posma
Nynke J. De Vries
Andrie C. Westerkamp
Petra J. Ottens
Daan J. Touw
Maarten W. Nijsten
Henri G.D. Leuvenink

CHAPTER 3

Abstract

Introduction
Metformin may act renoprotective prior to kidney transplantation by reducing ischemia-reperfusion injury (IRI). This study examined whether metformin preconditioning and postconditioning during ex vivo normothermic machine perfusion (NMP) of rat and porcine kidneys affect IRI.

Materials and methods
In the rat study, saline or 300 mg/kg metformin was administered orally twice on the day before nephrectomy. After 15 minutes of warm ischemia, kidneys were preserved with static cold storage for 24 hours. Thereafter, 90 minutes of NMP was performed with the addition of saline or metformin (30 or 300 mg/L). In the porcine study, after 30 minutes of warm ischemia, kidneys were preserved for 3 hours with oxygenated hypothermic machine perfusion. Subsequently, increasing doses of metformin were added during 4 hours of NMP.

Results
Metformin preconditioning of rat kidneys led to decreased injury perfusate biomarkers and reduced proteinuria. Postconditioning of rat kidneys resulted, dose-dependently, in less tubular cell necrosis and vacuolation. Heat shock protein 70 expression was increased in metformin-treated porcine kidneys. In all studies, creatinine clearance was not affected.

Conclusion
In conclusion, both metformin preconditioning and postconditioning can be done safely and improved rat and porcine kidney quality. Because the effects are minor, it is unknown which strategy might result in improved organ quality after transplantation.
Introduction

Kidney transplantation is the treatment of choice for patients with end-stage renal disease(1). Unfortunately, demand is higher than the availability of organs(2). This shortage has resulted in increased use of suboptimal quality organs from donation after circulatory death (DCD) donors(3). Kidneys from DCD donors are more susceptible to ischemia-reperfusion injury (IRI), which is linked to significantly higher incidences of delayed graft function, affecting both short-term and long-term outcome(4, 5). IRI is caused by the impairment of blood flow and subsequent reoxygenation, which results in the generation of reactive oxygen species (ROS), initiating a cascade of detrimental cellular responses(6, 7). The severity of ischemia correlates strongly with early renal graft failure after kidney transplantation and contributes to increased morbidity(8). Therefore, warm ischemia (WI) during organ retrieval and implantation, and cold ischemic time during preservation, respectively, should be kept to a minimum. Machine perfusion strategies can play a pivotal role in decreasing IRI by supplying oxygen during ischemic phases in organ donation. Furthermore, it provides a platform to add possible protective agents prior to reperfusion (preconditioning) or during reperfusion (postconditioning), and is a suitable method to assess short-term renal function and injury(9-11).

The biguanide metformin is the most used oral antihyperglycemic drug to treat patients with type 2 diabetes. The mechanism of action and the pleiotropic effects of metformin primarily results from the inhibition of complex 1 within the mitochondrial respiratory chain(12-14). Therefore, metformin may attenuate IRI beyond its glucose-lowering actions, and has been proposed as an organ-protective agent during circumstances in which IRI occurs, such as transplantation(15, 16).

The aim of this study was to evaluate potential beneficial effects of preconditioning and postconditioning with metformin on IRI in two different isolated ex vivo normothermic machine perfusion (NMP) models using rat and porcine kidneys.

Materials and methods

Rat study

Animals

Male Lewis rats weighing 270–300 g were used (Harlan Laboratories, Boxmeer, The Netherlands). The Institutional Animal Care and Use Committee of the University of Groningen approved the study protocol (DEC6708C). The animals received care according to the Dutch Law on Animal Experiments, following the National Institute of Health’s Principles of Laboratory Animal Care.
CHAPTER 3

Experimental design, organ retrieval and preservation

A total of 31 rats were divided into 6 groups \( n = 5–6 \) per group; Figure 1). In all groups, 15 minutes of WI and 24 hours of cold preservation was used to induce ischemic injury. Preconditioning was performed by administering 300 mg/kg metformin (1,1-dimethylbiguanide hydrochloride; Sigma-Aldrich, St. Louis, MO, USA) dissolved in saline (0.9% NaCl) or saline alone through oral gavage 12 and 2 hours before nephrectomy. Saline, 30 mg/L metformin or 300 mg/L metformin was added to the perfusate as postconditioning agent. The concentration of 300 mg/kg body weight was chosen, as this dose resulted in serum metformin concentrations that correspond to those found in humans during maintenance metformin therapy(17).

Rat study

<table>
<thead>
<tr>
<th>Preconditioning</th>
<th>Preservation</th>
<th>Postconditioning assessment</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Saline ( n=5 )</strong></td>
<td>15 min WI</td>
<td>Static cold storage for 24h</td>
</tr>
<tr>
<td><strong>Metformin ( n=5 )</strong></td>
<td>15 min WI</td>
<td>Static cold storage for 24h</td>
</tr>
<tr>
<td><strong>Saline ( n=5 )</strong></td>
<td>15 min WI</td>
<td>Static cold storage for 24h</td>
</tr>
<tr>
<td><strong>Metformin ( n=5 )</strong></td>
<td>15 min WI</td>
<td>Static cold storage for 24h</td>
</tr>
<tr>
<td><strong>Saline ( n=5 )</strong></td>
<td>15 min WI</td>
<td>Static cold storage for 24h</td>
</tr>
<tr>
<td><strong>Metformin ( n=6 )</strong></td>
<td>15 min WI</td>
<td>Static cold storage for 24h</td>
</tr>
</tbody>
</table>

Porcine study

<table>
<thead>
<tr>
<th>Control Group ( n=6 )</th>
<th>30 min WI</th>
<th>2h HMP without addition of metformin</th>
<th>4h NMP without addition of metformin</th>
</tr>
</thead>
<tbody>
<tr>
<td>Experimental group ( n=7 )</td>
<td>30 min WI</td>
<td>3h HMP with addition of 4mg/L metformin</td>
<td>4h NMP with increasing metformin dose</td>
</tr>
</tbody>
</table>

**Figure 1** — Schematic representation of the experimental groups. Groups contain 5–7 kidneys.

The procurement of kidneys was performed with minor changes to the DCD procedure, as described previously(18). In short, rats were anaesthetized with 2–5% isoflurane, and laparotomy was performed via a midline incision. Anticoagulation, using 500 IU heparin (Leo Pharma, Ballerup, Denmark), was administered via the dorsal penile vein. After 15 minutes of WI, nephrectomy of the left kidney was performed. The renal artery and ureter were cannulated. The kidney was flushed *in situ* with 10 mL saline (37°C) and 5 mL 4°C University of Wisconsin (UW) Cold Storage Solution (Bridge to Life, Columbia, SC, USA). Once removed, kidneys were flushed with 5 mL UW once again and stored in UW for 24 hours at 4°C.
Normothermic machine perfusion
The rat NMP method has been described extensively earlier.(18) In brief, NMP was performed for 90 minutes using a roller pump (Ismatec ISM404, Zürich, Switzerland). The perfusion pressure was set at 102 mmHg, controlled at the renal artery. In the control group, the perfusion fluid consisted of 100 mL William’s Medium E supplemented with 30 mmol/L HEPES, 50 g/L albumin, and 7 mmol/L creatinine (all Sigma-Aldrich). In the experimental groups, either 30 or 300 mg/L metformin was added to the perfusate. The perfusion fluid was oxygenated with 95% oxygen and 5% carbon dioxide with a flow of 0.5 L/min. The temperature of the perfusion fluid was maintained at 37°C using a water bath and heat exchanger (Julabo, Seelbach, Germany). The flow was recorded every 10 minutes, using a calibrated flow sensor (ME1PXN Inline, Transonic Systems, Ithaca, NY, USA). After NMP, biopsies of the kidneys were submerged immediately in 4% formaldehyde or snap-frozen in liquid nitrogen and subsequently stored at −80°C.

Porcine study

Animals
Kidneys from female Dutch Landrace pigs were collected from an abattoir. The animals were stunned and exsanguinated according to local standard procedures. During exsanguination, approximately 1 liter of blood was collected in a container containing 25,000 IU unfractionated heparin (Leo Pharma). Because slaughterhouse waste material was used, no animal ethics committee approval was required.

Experimental design, organ retrieval and preservation
To induce ischemic injury, 30 minutes of WI was used. After this period, the kidney was flushed with 180 mL saline at 4°C. Immediately after the flush, a cortical biopsy was taken (Invivo, Best, The Netherlands) and stored in 4% buffered formaldehyde. To accommodate transport from the abattoir to the laboratory and as a preservation technique, the renal artery was cannulated and the kidneys were attached to a pulsatile pressure-controlled hypothermic machine perfusion (HMP) setup (Kidney Assist Transport; Organ Assist, Groningen, The Netherlands). The kidneys were perfused at 4°C using 500 mL UW Machine Perfusion Solution for 3 hours (Bridge to Life, London, United Kingdom) with or without the addition of 2 mg metformin, with a mean arterial pressure of 25 mmHg. Oxygen (100%) was supplied to the oxygenator (Hilite LT 1000; Medos Medizintechnik AG, Stolberg, Germany) with a fixed flow rate of 0.1 L/min.
CHAPTER 3

Normothermic machine perfusion

The kidneys were reperfused using an ex vivo NMP setup for 4 hours that was described previously(11). In our study, increasing doses of metformin or saline were added using an infusion pump. In short, after HMP, the renal artery was cannulated and flushed. The ureter was cannulated for urine collection. Afterward, the kidney was weighed, and a biopsy was taken and stored in 4% buffered formaldehyde for further analysis. Subsequently, the kidneys were placed in an ex vivo pressure-controlled NMP circuit. NMP was performed with 500 mL leucocyte depleted, (BioR 02 plus; Fresenius Kabi, Bad Homburg, Germany) autologous, oxygenated (carbogen, flow 0.5 L/min) blood for 4 hours at a mean arterial pressure of 80 mmHg. Other compounds added to the perfusion fluid are provided in Supplementary Table 1. For each experiment, the flow was recorded using the clamp-on flow probe (ME7PXL; Transonic Systems), which was attached to the tubing close to the renal artery. This flow probe has been calibrated for the tubing used. Every 15 minutes during NMP, urine was collected and replaced with a corresponding volume of Ringer’s lactate solution, which was also recorded. The temperature of the perfusion fluid was maintained at 37°C using an integrated heat exchanger, connected to a water bath (Julabo). Blood and urine samples were taken after 15 and 60 minutes and every following hour for biochemical analyses. When NMP was finished, biopsies were taken and stored in 4% buffered formaldehyde, or snap-frozen and stored at −80°C for further analysis.

In the experimental group, metformin dissolved in Ringer’s lactate solution (20 mg/mL; Baxter, Utrecht, The Netherlands) was infused using an infusion pump controlled by custom-made software in which infusion profiles could be defined (Alaris; CareFusion, Rolle, Switzerland). Every 30 minutes during NMP, the infusion speed was increased according to a prespecified schedule (Supplementary Table 2). This schedule was based on human pharmacokinetic data indicating that metformin clearance is four times higher than the creatinine clearance(19). In the control group, kidneys were perfused without the addition of metformin.

Both studies

Biochemical analyses

Perfusate and urine samples were centrifuged (1300 g for 10 minutes in the rat model and 1000 g for 12 minutes in the porcine model, respectively, both at 4°C) and the supernatant was stored at −80°C. Lactate dehydrogenase (LDH), aspartate aminotransferase (ASAT), and creatinine were determined in perfusate, and creatinine in urine, respectively, by the Laboratory Center of the University Medical Center Groningen using standard biochemical analyses. The amount of protein excreted in rat urine was measured using a Pierce BCA Protein Assay (Thermo Fisher Scientific, Waltham, MA, USA), whereas total protein concentration
in porcine urine was measured using standard biochemical analyses at the Laboratory Center.

**Real-time quantitative polymerase chain reaction**

Real-time polymerase chain reaction (PCR) was carried out according to standard procedures on the Taqman Applied Biosystems 7900HT Real-Time PCR system, as described previously(20). Amplification of gene fragments involved in the regulation of vascular tone (endothelin 1 (EDN-1, encoding for ET-1); endothelial nitric oxide synthase (eNOS); and Krüppel-like factor 2 (KLF-2)), endothelial activation (Von Willebrand factor (vWF); vascular cell adhesion molecule 1 (VCAM-1) and IL-6)), and heat-shock protein 70 (HSP-70) was done with primer sets listed in Table S3. In short, total RNA was extracted from kidney sections using TRIzol (Life Technologies, Gaithersburg, MD). The cDNA obtained from rats was used as an internal reference during PCR to test primer efficiency. Gene expression was normalized with the mean of β-actin mRNA content. Results were expressed as \(2^{-\Delta\Delta CT}\), for which the CT value represents the difference between cycle threshold values.

**Morphological scoring**

Biopsies stored in 4% formaldehyde were embedded in paraffin and were cut into 4 µm slices. Coupes were subsequently stained with periodic acid-Schiff and scored on proximal tubular cell necrosis (ranging from mild to severe: 1–5), edema (ranging from mild to severe: 1–4), and proximal tubular cell vacuolation (ranging from mild to severe: 1–4)(21). Histopathological assessment was done blinded by two researchers. An independent clinical pathologist with extensive experience in assessing histopathological signs of injury after machine perfusion of rat and porcine organs validated the scores.

**Calculations**

Intrarenal vascular resistance (IVR) was calculated by dividing the mean arterial pressure by flow (expressed in mmHg/mL min⁻¹). Creatinine clearance was calculated to estimate glomerular filtration rate using the following equation: [creatinine in urine] * urine flow / [creatinine in perfusate].

**Statistical analysis**

All data are expressed as mean ± standard error of the mean. When comparing two groups at a single timepoint, differences were assessed using an unpaired Student’s t-test. Differences for total urine production, morphological scores, and gene expression were tested using analysis of variance. All statistical tests are two-tailed and \(P \leq 0.05\) was considered statistically significant. SPSS Statistics version 23 (IBM, Armonk, NY, USA) was used for all analyses. The area under the curve (AUC)
was calculated according to the trapezoid rule, and was used to approximate the total creatinine clearance, the total amount of protein excreted in the urine, and the total levels of ASAT and LDH in the perfusate.

Results

Perfusion parameters

The IVR remained constant during NMP in the rat model, without significant differences between the treatment groups (Supplementary Figure 1A). No significant differences were found in the porcine kidney groups regarding IVR (Supplementary Figure 1B).

Kidney function parameters

No significant differences in total creatinine clearance were observed between all treatment groups in the rat study (Figure 2A). In the porcine study, total creatinine clearance did not differ between metformin-treated kidneys and controls (Figure 2B), although there was a tendency toward lower creatinine clearance in the metformin-treated group ($P = 0.07$). Metformin-pretreated rats of whom kidneys were perfused with 30 mg/L metformin had a significantly lower urine production compared with rats pretreated with metformin without subsequent perfusion with metformin ($P = 0.02$), and rats pretreated with oral saline whose kidneys were postconditioned with 30 mg/L metformin ($P = 0.04$). Postconditioning with 300 mg/L metformin did not yield any significant difference in urine production, irrespective of preconditioning conditions. Compared with controls, total urine production in porcine kidneys was significantly lower in metformin-treated kidneys ($P = 0.004$; Figure 2C and 2D). In the rat study, total protein excretion was lower in metformin-preconditioned kidneys without subsequent perfusion with metformin than the control group ($P = 0.001$). No differences in total protein excretion were observed between all other experimental groups (Figure 2E). During NMP of porcine kidneys, no significant differences in urinary protein excretion were found between the metformin and control group (Figure 2F).

Injury markers

Metformin-preconditioned rats whose kidneys were not perfused with metformin had lower LDH release than controls ($P = 0.005$). Metformin-preconditioned rats whose kidneys subsequently were perfused with 30 mg/L metformin had lower LDH release than controls ($P = 0.01$) and had a lower LDH release than saline-preconditioned rats whose kidneys were perfused with 30 mg/L metformin ($P = 0.04$). Perfusion with 300 mg/L metformin did not result in decreased LDH release (Figure 3A). Total LDH release during NMP did not differ between metformin-
Metformin pre- and postconditioning to reduce ischemia reperfusion injury

Metformin pre- and postconditioning to reduce ischemia reperfusion injury

Compared with controls, tubular necrosis was significantly reduced in kidneys that were perfused with 300 mg/L metformin, independent of saline ($P = 0.02$) or metformin ($P = 0.02$) preconditioning. Metformin-preconditioned rats whose kidneys were perfused with 300 mg/L metformin had less tubular necrosis compared with metformin-preconditioned rats without subsequent metformin perfusion ($P = 0.01$) and metformin-preconditioned rats of whose kidneys were perfused with 30 mg/L metformin ($P = 0.02$; Figure 3E). Proximal tubular cell vacuolation was significantly reduced in saline-preconditioned rats whose kidneys were perfused with 300 mg/L metformin compared with saline-preconditioned rats whose kidneys were perfused with 30 mg/L metformin ($P = 0.05$). Vacuolation was also significantly lower in metformin-preconditioned kidneys perfused with 300 mg/L metformin compared with metformin-preconditioned kidneys without metformin perfusion ($P = 0.02$) (Figure 3G). No statistical differences regarding edema formation were seen in the rat study (Figure 3F). No differences in morphological signs of IRI were observed at the end of NMP in porcine kidneys (Figure 3H).
Figure 2 — Perfusion and renal function parameters assessed during and after normothermic machine perfusion of rat and porcine kidneys. Total creatinine clearance of rat (A) and porcine (B) kidneys. Total urine production (C, D) and total protein excreted in the urine (E, F) of rat and porcine kidneys, respectively. Data are presented as mean ± standard error of the mean. Groups contain 5–7 kidneys. *P < 0.05 and **P < 0.01.
Figure 3 — Injury markers in perfusion fluid and morphological injury in tissue after normothermic machine perfusion. Total markers of injury were calculated as the area under the curve. Total amount of lactate dehydrogenase (LDH) (A, B) and aspartate aminotransferase (ASAT) (C, D) in the perfusate. Tissue was scored on proximal tubular cell necrosis (ranging from mild to severe: 1–5), edema (ranging from mild to severe: 1–4), and proximal tubular cell vacuolation (ranging from mild to severe: 1–4) in the rat study, respectively (E–G). Signs of ischemia reperfusion injury in porcine kidneys were scored (h). Data are presented as mean ± standard error of the mean. Groups contain 5–7 kidneys. *P < 0.05, **P < 0.01, compared with all other groups.
Gene expression
Relative mRNA expression of genes involved in the regulation of the vascular tone was evaluated in both rat and porcine kidneys. Compared with controls, the expression of EDN-1 was significantly decreased in rat kidneys perfused with 300 mg/L metformin, regardless of preconditioning with saline ($P = 0.002$) or metformin ($P = 0.005$; Figure 4A). Compared with saline-pretreated rats whose kidneys were perfused with 30 mg/L metformin, eNOS expression was significantly decreased in controls ($P = 0.04$) and saline-preconditioned rats whose kidneys were perfused with 300 mg/L metformin ($P = 0.01$; Figure 4B). No differences regarding EDN-1 or eNOS expression were found in the porcine kidney study (Figure 4H). KLF-2 expression was not different between groups in both the rat and porcine kidney study (Figure 4C and 4H).

Moreover, genes involved in endothelial activation were evaluated. The vWF expression did not differ between treatment groups in both rat and porcine kidneys (Figure 4D and 4I). Compared with controls, gene expression of VCAM-1 was significantly decreased in rat kidneys perfused with 30 mg/L metformin irrespective of preconditioning with saline ($P = 0.002$) or metformin ($P = 0.03$). Saline-pretreated rats whose kidneys were perfused with 30 mg/L metformin had lower VCAM-1 expression than metformin-preconditioned rats whose kidneys were also perfused with 30 mg/L metformin ($P = 0.04$). Saline-preconditioned rats whose kidneys were perfused with 300 mg/L metformin had significantly higher VCAM-1 expression than saline-preconditioned rats whose kidneys were perfused with 30 mg/L metformin ($P = 0.002$). On the other hand, metformin-preconditioned rats whose kidneys were perfused with 300 mg/L metformin had significantly higher VCAM-1 expression than controls ($P = 0.03$; Figure 4E).

Compared with metformin-preconditioned rats whose kidneys were perfused with 300 mg/L metformin, IL-6 gene expression was decreased in metformin-preconditioned rats whose kidneys were not perfused with metformin ($P = 0.03$), and metformin-preconditioned rats whose kidneys were perfused with 30 mg/L metformin ($P = 0.004$; Figure 4F). HSP-70 expression in rat kidneys was not different between treatment groups (Figure 4G). Expression of vWF, VCAM-1, and IL-6 was not significantly different between experimental groups within the porcine kidney study (Figure 4I). However, HSP-70 was upregulated in metformin-treated porcine kidneys ($P = 0.03$; Figure 4I).
Metformin pre- and postconditioning to reduce ischemia reperfusion injury

**Figure 4** — Relative mRNA expression of genes involved in the regulation of vascular tone, including vasoconstriction (endothelin 1 (EDN-1)), vasodilatation (endothelial nitric oxide synthase (eNOS)), and laminar flow shear stress (Krüppel-like factor 2 (KLF-2)) in both the rat (respectively, a–c) and porcine study (h). Genes involved in the activation of the endothelium, playing a role in platelet (von Willebrand factor (vWF)) and leukocyte adhesion (vascular cell adhesion molecule 1 (VCAM-1)), and inflammatory processes (IL-6) were assessed in rat (respectively, d–f) and porcine kidneys (i). Heat-shock protein 70 (HSP-70) expression was evaluated as well in both rat and porcine kidneys (respectively, g, i). Data are presented as mean ± standard error of the mean. Groups contain 5–7 kidneys. *P < 0.05, **P < 0.01.
Discussion

The aim of this study was to evaluate potential benefits of metformin preconditioning and postconditioning on IRI in two distinct ex vivo NMP models using rat and pig kidneys. We found that, in terms of renal function, metformin preconditioning was associated with significantly lower proteinuria, representing a favorable effect on glomerular integrity(22). In terms of cellular injury, significantly lower LDH values were observed in preconditioned rat kidneys, whereas postconditioning was not associated with differences in this biomarker. Interestingly, postconditioning with 300 mg/L metformin resulted in less tubular cell necrosis and vacuolation. Furthermore, metformin preconditioning and postconditioning resulted in gene expression upregulation of genes encoding for endothelial activation and inflammation in rats and a significant upregulation of HSP-70 in metformin-perfused porcine kidneys. The results from this study are indicative that metformin has indeed beneficial effects on renal integrity, albeit these effects are minimal and not conclusive. Therefore, we did not find a clear answer on whether and in which modality metformin can be used as a renoprotective strategy to reduce IRI.

To increase the robustness of our findings and to reduce potential interspecies effects, two methodological distinct ex vivo experimental NMP models were used in our study. Because the models differed in so many ways, we do not believe the results can be compared directly, but should be interpreted as two separate albeit complementary studies. However, we found beneficial effects of metformin in the rat study, whereas no apparent differences were found in the porcine experiments. This might be explained by differences in experimental design. Metformin was administered to rats as a preconditioning agent, whereas metformin was only added to porcine kidneys during HMP and NMP as a postconditioning agent. Because porcine kidneys were obtained from the abattoir, we were not able to perform any preconditioning actions. Second, metformin was given at the start of NMP in the rat study, whereas porcine kidneys were exposed to increasing doses over time. Third, both studies used organs from different sexes. Therefore, potential gender effects could have arisen, as previous studies showed differences in effects of brain death on IRI and microcirculation between sexes(23, 24). Moreover, even sex-dependent differences in the anticancer effects of metformin have been reported(25). Whether this is also the case with metformin used in transplantation settings is worth elucidating.

Remarkably, the administration of metformin in concentrations that are associated with toxicity in humans was not associated with cellular injury in both our ex vivo models. This is an important finding because metformin can accumulate in patients with renal insufficiency and who subsequently can develop severe lactic acidosis(19, 26). Our study shows that administration of metformin in high
Metformin pre- and postconditioning to reduce ischemia reperfusion injury

doses does not induce cellular injury and, therefore, could be safely used in ex vivo machine perfusion setups.

Previously, it is reported that preconditioning with metformin can reduce IRI(27-29). Protective effects of metformin were observed during cerebral ischemia and subsequent reperfusion in rats(29, 30). In murine myocardial infarction models, administration of metformin before ischemia or during reperfusion was associated with decreased infarction size(28, 31). However, these results could not be reproduced in a swine model(32). Metformin has also been clinically studied as a preconditioning agent to reduce IRI. However, neither beneficial effects on myocardial injury nor other IRI-reducing effects of metformin preconditioning were found in these randomized clinical trials(33, 34). Postconditioning with metformin has also been assessed clinically, in which no effects of metformin treatment initiated after myocardial infarction were observed on renal function or left ventricular function(35, 36). In previous experiments performed by our group, metformin preconditioning of donor rat livers was able to improve hepatobiliary function during NMP and orthotopic liver transplantation thereafter(37).

The exact mechanism of action of metformin is unknown, but mild inhibition of complex 1 within the mitochondrial electron transport chain seems to play a pivotal role(12-14). Moreover, metformin is thought to affect endothelial function through several distinct pathways, including regulation of nitric oxide production, inhibition of apoptosis, and alteration of the cellular energy state with subsequent activation of kinase pathways(38-40). In line with previous experiments, postconditioning with 300 mg/L metformin decreases expression of ET-1(39, 41). Endothelin 1 has proinflammatory effects, stimulates ROS production, and modifies the glomerular barrier(42). Moreover, elevated ET-1 is associated with vascular and kidney injury(43, 44). Increased expression of eNOS was found in rat kidneys perfused with a low dose of metformin, which is associated with decreased IRI and oxidative stress(38, 44, 45). However, no differences in KLF-2, a marker of fluid laminar shear stress, or in vascular resistance itself, were observed. Expression of VCAM-1 correlates with severe structural damage of renal parenchyma, and has previously been reported to be less abundant in the metformin-treated kidneys(46, 47). Moreover, expression of VCAM-1, also involved in leukocyte adhesion, can be induced by ROS in endothelial cells during inflammation(48). Indeed, we found reduced VCAM-1 expression in kidneys perfused with 30 mg/L metformin. Summarizing, the findings in gene expression suggest that endothelial activation was moderately affected by exposure to metformin.

In our study, we mainly observed a protective effect of preconditioning with metformin, implying that metformin needs to be administered before the ischemic insult. Therefore, a donor intervention should be considered in a transplantation
setting. Diminishing organ injury by changing donor management has been proposed and is performed sparsely by others (49, 50). However, the logistical and ethical issues concerning donor-intervention research hamper performing randomized controlled trials. Furthermore, the proposed intervention should not negatively affect other organs that are supposed to be transplanted. Therefore, for now, the only likely translational use would be \textit{ex vivo} postconditioning with metformin. Machine perfusion modalities are increasingly used and are offering an ideal platform for pharmacological interventions, like metformin. As postconditioning with metformin showed some modest beneficial effects in our study, it might be tested as a renoprotective agent in future research. However, our results do not necessarily advocate the use of metformin as a pharmacological intervention prior to kidney transplantation, and we suggest it can be considered to be tested in combination with other potential treatments.

A limitation reducing the clinical translational aspect of our study is the lack of a full kidney transplantation after NMP, which should be the direction for further research in this field and our study may, therefore, be considered as a step toward a transplantation experiment. Another limitation of our study was that we did not measure urinary markers of acute injury, like kidney injury molecule 1. However, we did measure indicators of renal injury, like LDH and ASAT, that only showed minor beneficial effects of metformin treatment. Future research should comprehend these markers when examining effects of metformin on renal IRI.

In conclusion, although modest, metformin preconditioning prior to NMP was associated with reduced IRI possibly by protecting renal integrity, whereas postconditioning with metformin was associated with reduced tubular cell necrosis and vacuolation, as well as improved endothelial gene expression. Importantly, no safety signals or potentially irreversible damage was observed when exposed to \textit{in vivo} toxic metformin concentrations, indicating that it seems to be safe to use these concentrations of metformin during machine perfusion. Our study indicates that both metformin preconditioning and postconditioning improved rat and porcine kidney quality. However, these effects were minor and it remains unclear whether metformin can be used as renoprotective strategy during machine perfusion before renal transplantation.
Metformin pre- and postconditioning to reduce ischemia reperfusion injury

References


